Tags

Type your tag names separated by a space and hit enter

Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose?
Front Oncol. 2022; 12:940582.FO

Abstract

Beta-blockers are currently studied to improve therapeutic options for patients with angiosarcoma. However, most of these patients have no cardiovascular co-morbidity and it is therefore crucial to discuss the most optimal pharmacological properties of beta-blockers for this population. To maximize the possible effectiveness in angiosarcoma, the use of a non-selective beta-blocker is preferred based on in vitro data. To minimize the risk of cardiovascular adverse events a beta-blocker should ideally have intrinsic sympathomimetic activity or vasodilator effects, e.g. labetalol, pindolol or carvedilol. However, except for one case of carvedilol, only efficacy data of propranolol is available. In potential follow-up studies labetalol, pindolol or carvedilol can be considered to reduce the risk of cardiovascular adverse events.

Authors+Show Affiliations

Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands.Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands.Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands.Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands.Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands. Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands. Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

36185303

Citation

Embaby, Alaa, et al. "Beta-adrenergic Receptor Blockade in Angiosarcoma: Which Beta-blocker to Choose?" Frontiers in Oncology, vol. 12, 2022, p. 940582.
Embaby A, van Merendonk L, Steeghs N, et al. Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose? Front Oncol. 2022;12:940582.
Embaby, A., van Merendonk, L., Steeghs, N., Beijnen, J., & Huitema, A. (2022). Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose? Frontiers in Oncology, 12, 940582. https://doi.org/10.3389/fonc.2022.940582
Embaby A, et al. Beta-adrenergic Receptor Blockade in Angiosarcoma: Which Beta-blocker to Choose. Front Oncol. 2022;12:940582. PubMed PMID: 36185303.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose? AU - Embaby,Alaa, AU - van Merendonk,Lisanne, AU - Steeghs,Neeltje, AU - Beijnen,Jos, AU - Huitema,Alwin, Y1 - 2022/09/15/ PY - 2022/05/10/received PY - 2022/08/30/accepted PY - 2022/10/3/entrez PY - 2022/10/4/pubmed PY - 2022/10/4/medline KW - angiosarcoma KW - beta-blockade KW - drug repurposing KW - pharmacological characteristics KW - propranolol SP - 940582 EP - 940582 JF - Frontiers in oncology JO - Front Oncol VL - 12 N2 - Beta-blockers are currently studied to improve therapeutic options for patients with angiosarcoma. However, most of these patients have no cardiovascular co-morbidity and it is therefore crucial to discuss the most optimal pharmacological properties of beta-blockers for this population. To maximize the possible effectiveness in angiosarcoma, the use of a non-selective beta-blocker is preferred based on in vitro data. To minimize the risk of cardiovascular adverse events a beta-blocker should ideally have intrinsic sympathomimetic activity or vasodilator effects, e.g. labetalol, pindolol or carvedilol. However, except for one case of carvedilol, only efficacy data of propranolol is available. In potential follow-up studies labetalol, pindolol or carvedilol can be considered to reduce the risk of cardiovascular adverse events. SN - 2234-943X UR - https://www.unboundmedicine.com/medline/citation/36185303/Beta-adrenergic_receptor_blockade_in_angiosarcoma:_Which_beta-blocker_to_choose DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.